ArticleInternational journal of environmental research and public health2022
Personalised Dosing Using the CURATE.AI Algorithm: Protocol for a Feasibility Study in Patients with Hypertension and Type II Diabetes Mellitus.
Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Preliminary insights into artificial intelligence guided dosing in hypertension and diabetes: challenges and lessons learnt in a pilot feasibility study.JAMIA open · 2026Article
- From Innovation to Integration: Bridging the Gap Between IoMT Technologies and Real-World Health Management Systems.Sensors (Basel, Switzerland) · 2025Article
- Artificial intelligence guided dosing decisions: a qualitative study on health care provider perspectives.BMJ health & care informatics · 2025Article
- Digital Alchemy: The Rise of Machine and Deep Learning in Small-Molecule Drug Discovery.International journal of molecular sciences · 2025Review
- The role of nanomedicine and artificial intelligence in cancer health care: individual applications and emerging integrations-a narrative review.Discover oncology · 2025Review
- A Comprehensive Investigation: Developing the Pharmaceutical Industry through Artificial Intelligence.Current drug discovery technologies · 2025Review
- Enhancing Tumor Targeted Therapy: The Role of iRGD Peptide in Advanced Drug Delivery Systems.Cancers · 2024Review
- Article
- Bayesian Networks in the Management of Hospital Admissions: A Comparison between Explainable AI and Black Box AI during the Pandemic.Journal of imaging · 2024Article
- N-of-1 medicine.Singapore medical journal · 2024Article
- Simulation and Optimization: A New Direction in Supercritical Technology Based Nanomedicine.Bioengineering (Basel, Switzerland) · 2023Review
- The Emergence of AI-Based Wearable Sensors for Digital Health Technology: A Review.Sensors (Basel, Switzerland) · 2023Review
- Physicians' Perspectives on AI in Clinical Decision Support Systems: Interview Study of the CURATE.AI Personalized Dose Optimization Platform.JMIR human factors · 2023Article
- Review
- Application of Artificial Intelligence in the Diagnosis, Treatment, and Prognostic Evaluation of Mediastinal Malignant Tumors.Journal of clinical medicine · 2023Review
- A Review of Advanced Multifunctional Magnetic Nanostructures for Cancer Diagnosis and Therapy Integrated into an Artificial Intelligence Approach.Pharmaceutics · 2023Review
- Revolutionising healthcare with artificial intelligence: A bibliometric analysis of 40 years of progress in health systems.Digital healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic diseases typically require long-term management through healthy lifestyle practices and pharmacological intervention. Although efficacious treatments exist, disease control is often sub-optimal leading to chronic disease-related sequela. Poor disease control can partially be explained by the 'one size fits all' pharmacological approach. Precision medicine aims to tailor treatments to the individual. CURATE.AI is a dosing optimisation platform that considers individual factors to improve the precision of drug therapies. CURATE.AI has been validated in other therapeutic areas, such as cancer, but has yet to be applied in chronic disease care. We will evaluate the CURATE.AI system through a single-arm feasibility study (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.